RespireRx Pharmaceuticals Inc. announced that it has entered into a securities purchase agreement to issue a Demand Promissory Note at a price of $100,000 in the principal amount of $100,000 for gross proceeds of $100,000 and a Warrant exercisable into 33,333,333 shares of company's common stock at an exercise price of $0.0015 per share on April 10, 2024. The Demand Promissory Note accrues interest at the rate of 10% per annum based on a 365/366 day year, as applicable. Principal and interest are payable on demand of the lender.

Accrued unpaid interest is added to principal at the end of the year that principal is unpaid. The Warrant is exercisable in whole or in part at any time from the issuance date to the expiration date which is five years from the initial exercise date. The transaction included participation from new individual investor Dariusz Nasiek and Sara Nasiek, JTTEN.

Dariusz Nasiek is a member of the Board of Directors of the Company. The securities issued are pursuant to Rule 501 of Regulation D under the Securities Act.